Tag Archive for: Spinraza

Biogen Inc. (BIIB.O) Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer’s disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth.

Even with the COVID-19 emergency measures, payers still had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline, and were pondering new ways to pay for them.